Giovanni Caforio, Bristol Myers Squibb CEO (The Galien Foundation)
August 23, 2023 02:51 PM EDT
Pharma
Marketing

Bris­tol My­ers touts ear­ly so­cial and en­vi­ron­men­tal progress among achieve­ments in lat­est ESG re­port

Beth Snyder Bulik

Senior Editor

A boost for di­ver­si­ty in clin­i­cal tri­als and an ear­li­er-than-ex­pect­ed $1 bil­lion spend with mi­nor­i­ty-owned busi­ness­es are some of the high­lights in Bris­tol My­ers Squibb’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times